C4 - Collaborate to innovate – Building a healthier future for patients

Auditorium 2

Organised by the FIP Community Pharmacy Section in collaboration with FIP’s Industrial Pharmacy Section

Chairs

Ulf Janzon, Sveriges Farmaceuter, Sweden and Leonila Ocampo, Philippine Pharmacists Association, Philippines

Introduction

Innovation is in pharmacist’s DNA. Innovation is a vehicle by which we improve patients’ quality of life, evolve the way we manage healthcare and benefit wider society. When a new innovative medicine is developed, education of healthcare professionals and pharmacist is required to ensure the appropriate use by patients in order to optimize treatments and outcomes and to reduce harm and risk. Collaboration is a key to the successful innovation so that the impact of the innovation of quality of life is positive.

Developing a health care system that supports innovations to reach market and ultimately the patient, while allowing patients at the center of their own care, has become a consistent goal of most governments. This becomes even more important as medicines are becoming highly complex and technologically advanced, sometimes associated with the high price tag as well.

Technology has the potential to change several aspects of healthcare from helping discover new treatments to managing how we deliver patient care. For example, technology like the internet of things and sensors is already showing potential for remotely monitoring patients. There is also scope for more tech partnerships with pharmaceutical industry to develop products that help to realize the vision of delivering personalized medicines.

Patients are no longer content to be passive receivers of healthcare but instead want to shape it around their needs.Technology is likely to help in engaging with patients and they also are likely to benefit from the insights they have into the disease they are trying to treat. Collaborating with patients is said to lead to “better trials, better engagement, better communication throughout the entire life cycle of medicines—and ultimately better patient outcomes.

Traditionally, pharmaceutical companies may not have embraced collaborative working, but now it has become more common. With new technology, both for patients and medical staff and how diseases are becoming more sophisticated, collaboration between the patient, the pharmaceutical industry, healthcare professionals and pharmacists is the key.  

Programme

09:00 – 09:10 Introduction by the chairs

09:10 – 09:45
1. Pipelines are full of new exciting medicines – How does the technology help in medicines development, and the way medical information reaches healthcare professionals and patients timely and accurately to improve their treatment and quality of life developed

Kerstin Wagner, Johnson & Johnson, USA

09:45 – 10:20
2. Hurdles to overcome to bring new innovative treatments for the use of governments and patients

Anne Lee, Scottish Medicines Consortium, UK

10:20 – 10:40 Coffee/tea break

10:40 – 11:15
3. Bridging the competence gap for pharmacists of new technologies

Debra Rowett, University of South Australia, Australia

11:15 – 11:50
4. The role of pharmacy in the successful delivery of advanced therapy medicinal products
Neil Watson, Pharmacy Directorate Royal Victoria Infirmary, UK

11:50 – 12:00 Conclusion by the chairs

Learning Objectives

At the end of this session, participants will be able to:

  1. Describe what value new technological innovations can have on the whole value chain: medicines development, pharmacists and physician tole and the patient
  2. Explore the value of having patients involved in the development of new medicines
  3. Understand the limitations the new innovative therapies might have from market access/pricing perspective
  4. Embrace the need for continuing education for pharmacists and their evolving role regarding new medicines